Qing-lang Li1, Yue-fei Zhang. 1. Department of Cardiology, Affiliated Tongren Hospital, Capital Medical University, Beijing 100730.
Abstract
OBJECTIVE: To grasp the therapeutic effect of Taizhi'an (TZA) in lowering blood lipid level. METHODS:Three hundred patients with hyperlipidemia were randomly divided adopting numerical table method into 7 groups, the Taizhi'an group (A, n = 90), the half-dose Fenofibrate plus Taizhi'an group (B, n = 30), the full-dose Fenofibrate group (C, n = 30), the half-dose Simvastatin plus Taizhi'an group (D, n = 30), the full-dose Simvastatin group (E, n = 30), the Zhibituo group (F, n = 60) and the Xuezhikang group (G, n = 30). The effect in different groups were compared after 8 weeks treatment. RESULTS: In group A, the total cholesterol (TC) lowered by 12.7%, triglyceride (TG) lowered by 22.1% and the high density lipoprotein cholesterol (HDL-C) increased by 13.1%, the total effective rate being 82%. The therapeutic effect in group B was similar to that in group C, and that in group D was similar to that in group E (P > 0.05). The therapeutic effect of Taizhi'an was similar to that of Xuezhikang and Zhibituo, but was better than Zhibituo in lowering TG, LDL-C and increasing HDL-C, and better than Xuezhikang in lowering TG and increasing HDL-C (P < 0.05). CONCLUSION: When Taizhi'an used in combination with half-dose Simvastatin, it could not only enhance the blood lipid regulatory effect of Simvastatin but also reduce the dosage used and alleviate its adverse reaction. Compared with Xuezhikang and Zhibituo, Taizhi'an got the similar therapeutic effect, but was superior in regulating blood lipids.
RCT Entities:
OBJECTIVE: To grasp the therapeutic effect of Taizhi'an (TZA) in lowering blood lipid level. METHODS: Three hundred patients with hyperlipidemia were randomly divided adopting numerical table method into 7 groups, the Taizhi'an group (A, n = 90), the half-dose Fenofibrate plus Taizhi'an group (B, n = 30), the full-dose Fenofibrate group (C, n = 30), the half-dose Simvastatin plus Taizhi'an group (D, n = 30), the full-dose Simvastatin group (E, n = 30), the Zhibituo group (F, n = 60) and the Xuezhikang group (G, n = 30). The effect in different groups were compared after 8 weeks treatment. RESULTS: In group A, the total cholesterol (TC) lowered by 12.7%, triglyceride (TG) lowered by 22.1% and the high density lipoprotein cholesterol (HDL-C) increased by 13.1%, the total effective rate being 82%. The therapeutic effect in group B was similar to that in group C, and that in group D was similar to that in group E (P > 0.05). The therapeutic effect of Taizhi'an was similar to that of Xuezhikang and Zhibituo, but was better than Zhibituo in lowering TG, LDL-C and increasing HDL-C, and better than Xuezhikang in lowering TG and increasing HDL-C (P < 0.05). CONCLUSION: When Taizhi'an used in combination with half-dose Simvastatin, it could not only enhance the blood lipid regulatory effect of Simvastatin but also reduce the dosage used and alleviate its adverse reaction. Compared with Xuezhikang and Zhibituo, Taizhi'an got the similar therapeutic effect, but was superior in regulating blood lipids.